See more : Marsh & McLennan Companies, Inc. (MSN.DE) Income Statement Analysis – Financial Results
Complete financial analysis of Ceapro Inc. (CRPOF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ceapro Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Rejuvel Bio-Sciences, Inc. (NUUU) Income Statement Analysis – Financial Results
- MGM Growth Properties LLC (MGP) Income Statement Analysis – Financial Results
- Mitsubishi UFJ Financial Group, Inc. (MUFG) Income Statement Analysis – Financial Results
- Downing FOUR VCT plc (D4G.L) Income Statement Analysis – Financial Results
- Argent Minerals Limited (ARDNF) Income Statement Analysis – Financial Results
Ceapro Inc. (CRPOF)
About Ceapro Inc.
Ceapro Inc., a biotechnology company, engages in the development and marketing of health and wellness products and technology relating to plant extracts in the United States, Germany, China, Canada, and internationally. It operates in two segments, Active Ingredient Product Technology Industry and Cosmeceutical Industry. The Active Ingredient Product Technology Industry segment develops proprietary extraction technologies and the application of these technologies to the production, development, and commercialization of active ingredients, such as oat beta glucan and avenanthramides, which are derived from oats and other renewable plant resources for healthcare and cosmetic industries. The Cosmeceutical Industry segment is involved in the development and commercialization of anti-aging products derived from natural active ingredients sold directly to the end-user primarily through online website sales and through select natural products stores. The company was incorporated in 1997 and is headquartered in Edmonton, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.63M | 18.84M | 17.20M | 15.12M | 12.88M | 11.59M | 12.93M | 13.67M | 10.67M | 8.89M | 6.52M | 5.17M | 5.79M | 5.58M | 4.37M | 4.23M | 3.45M | 3.31M | 2.68M | 1.96M | 2.22M | 1.51M | 1.15M | 808.85K | 300.00K | 400.00K | 2.30M | 600.00K |
| Cost of Revenue | 6.07M | 7.82M | 7.51M | 7.50M | 7.43M | 5.45M | 5.65M | 4.32M | 3.64M | 4.13M | 3.43M | 2.72M | 2.54M | 3.04M | 2.25M | 2.64M | 1.79M | 1.73M | 1.12M | 1.02M | 928.12K | 754.13K | 728.41K | 517.68K | 200.00K | 100.00K | 1.90M | 500.00K |
| Gross Profit | 3.56M | 11.02M | 9.69M | 7.62M | 5.45M | 6.14M | 7.27M | 9.35M | 7.03M | 4.76M | 3.10M | 2.45M | 3.25M | 2.54M | 2.12M | 1.59M | 1.65M | 1.58M | 1.56M | 934.13K | 1.29M | 757.38K | 421.03K | 291.17K | 100.00K | 300.00K | 400.00K | 100.00K |
| Gross Profit Ratio | 36.99% | 58.48% | 56.35% | 50.41% | 42.28% | 52.95% | 56.26% | 68.40% | 65.89% | 53.58% | 47.50% | 47.41% | 56.13% | 45.46% | 48.47% | 37.53% | 47.97% | 47.70% | 58.13% | 47.73% | 58.16% | 50.11% | 36.63% | 36.00% | 33.33% | 75.00% | 17.39% | 16.67% |
| Research & Development | 2.75M | 1.79M | 3.78M | 1.88M | 2.39M | 2.67M | 1.61M | 919.12K | 625.21K | 578.36K | 731.17K | 856.19K | 996.72K | 774.06K | 0.00 | 0.00 | 695.66K | 365.42K | 162.83K | 302.49K | 353.74K | 259.06K | 397.00K | 293.43K | 400.00K | 800.00K | 2.30M | 100.00K |
| General & Administrative | 7.42M | 3.70M | 3.24M | 3.28M | 2.95M | 3.00M | 2.84M | 2.19M | 2.52M | 1.98M | 1.71M | 1.80M | 1.37M | 1.30M | 1.68M | 1.69M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 40.48K | 29.56K | 47.12K | 111.04K | 425.23K | 225.55K | 32.11K | 4.33K | 7.62K | 13.70K | 84.90K | 198.65K | 111.36K | 69.51K | 183.69K | 385.13K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.07M | 3.73M | 3.29M | 3.39M | 3.38M | 3.23M | 2.87M | 2.19M | 2.53M | 2.00M | 1.79M | 1.99M | 1.49M | 1.37M | 1.86M | 2.07M | 1.68M | 1.36M | 1.24M | 963.92K | 1.27M | 814.11K | 691.92K | 777.79K | 800.00K | 1.10M | 3.70M | 1.80M |
| Other Expenses | 129.31K | 181.46K | 273.12K | -93.71K | -353.32K | -1.12M | -738.09K | -629.30K | 0.00 | 0.00 | 0.00 | 0.00 | -7.34K | -479.44K | -219.38K | -2.29M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 9.82M | 5.52M | 7.07M | 5.28M | 5.77M | 5.17M | 6.63M | 3.11M | 3.15M | 2.58M | 2.53M | 2.85M | 2.48M | 1.43M | 1.90M | 2.81M | 2.17M | 1.87M | 1.56M | 1.36M | 1.68M | 1.10M | 1.11M | 1.10M | 1.20M | 2.00M | 8.20M | 2.20M |
| Cost & Expenses | 15.89M | 13.34M | 14.57M | 12.77M | 13.21M | 10.62M | 12.29M | 7.43M | 6.79M | 6.70M | 5.95M | 5.57M | 5.02M | 4.47M | 4.16M | 5.45M | 3.96M | 3.61M | 2.69M | 2.38M | 2.61M | 1.85M | 1.84M | 1.62M | 1.40M | 2.10M | 10.10M | 2.70M |
| Interest Income | 436.22K | 93.20K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.55K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 100.00K |
| Interest Expense | 128.13K | 129.97K | 151.89K | 175.16K | 201.50K | 48.05K | 20.03K | 37.59K | 52.78K | 63.51K | 126.66K | 112.90K | 180.81K | 110.90K | 77.03K | 83.65K | 43.83K | 46.35K | 51.70K | 28.50K | 47.77K | 93.56K | 113.22K | 94.93K | 0.00 | 100.00K | 0.00 | 100.00K |
| Depreciation & Amortization | 1.95M | 1.91M | 1.88M | 1.84M | 1.83M | 578.60K | 326.10K | 359.45K | 392.32K | 296.38K | 292.64K | 292.53K | 297.28K | 290.64K | 356.96K | 336.57K | 120.44K | 146.78K | 161.55K | 91.96K | 59.96K | 23.57K | 24.25K | 27.99K | 0.00 | 100.00K | 2.20M | 300.00K |
| EBITDA | -4.31M | 7.54M | 4.72M | 4.04M | 1.10M | 371.48K | 110.92K | 6.40M | 4.08M | 2.36M | 866.33K | -109.12K | 1.06M | 1.41M | 571.46K | -889.10K | -393.57K | -148.94K | 158.33K | -332.28K | -330.37K | -315.78K | -667.88K | -780.05K | -1.10M | -1.60M | -5.60M | -1.80M |
| EBITDA Ratio | -44.73% | 40.00% | 27.46% | 26.71% | 8.52% | 3.20% | 0.86% | 46.78% | 38.20% | 26.54% | 13.28% | -2.11% | 18.37% | 25.22% | 13.08% | -21.03% | -11.42% | -4.50% | 5.90% | -16.98% | -14.89% | -20.89% | -58.10% | -96.44% | -366.67% | -400.00% | -243.48% | -300.00% |
| Operating Income | -6.26M | 5.31M | 2.42M | 2.12M | -586.66K | 128.08K | 2.66M | 6.00M | 3.63M | 2.00M | 447.03K | -514.55K | 584.91K | 992.80K | 137.47K | -1.31M | -514.01K | 21.64K | -3.22K | -424.24K | -390.33K | -339.35K | -692.14K | -808.04K | -1.10M | -1.70M | -7.80M | -2.10M |
| Operating Income Ratio | -64.93% | 28.21% | 14.05% | 13.99% | -4.55% | 1.10% | 20.55% | 43.87% | 34.03% | 22.49% | 6.85% | -9.96% | 10.11% | 17.80% | 3.15% | -30.97% | -14.91% | 0.65% | -0.12% | -21.68% | -17.60% | -22.45% | -60.21% | -99.90% | -366.67% | -425.00% | -339.13% | -350.00% |
| Total Other Income/Expenses | 350.72K | 277.94K | -4.61K | -490.51K | -810.06K | -1.05M | -1.07M | -878.91K | -658.56K | -596.51K | -401.99K | -23.81K | -7.34K | 310.10K | -219.38K | -2.29M | -875.32K | -294.00K | -53.79K | 26.51K | 553.01K | 462.33K | 459.25K | -12.92K | 100.00K | -12.50M | -11.00M | -1.40M |
| Income Before Tax | -5.90M | 5.78M | 2.62M | 1.86M | -1.14M | -921.23K | -426.82K | 5.36M | 3.83M | 1.59M | 175.81K | -538.35K | 577.57K | 501.08K | -81.90K | -3.60M | -1.39M | -272.36K | -57.01K | -397.74K | 442.04K | 115.77K | -232.88K | -820.96K | -1.00M | -14.20M | -18.80M | -3.50M |
| Income Before Tax Ratio | -61.29% | 30.66% | 15.23% | 12.27% | -8.82% | -7.95% | -3.30% | 39.22% | 35.94% | 17.93% | 2.69% | -10.42% | 9.98% | 8.99% | -1.87% | -85.13% | -40.30% | -8.23% | -2.12% | -20.32% | 19.93% | 7.66% | -20.26% | -101.50% | -333.33% | -3,550.00% | -817.39% | -583.33% |
| Income Tax Expense | -1.19M | 1.38M | -223.69K | 81.45K | -3.41K | -605.69K | 531.46K | 1.74M | -1.09M | 63.51K | 126.66K | 112.90K | 180.81K | 123.18K | 64.48K | 83.65K | 369.93K | 46.35K | 51.70K | 28.50K | 47.77K | 93.56K | 113.22K | 94.93K | -100.00K | 100.00K | 1.00M | 200.00K |
| Net Income | -4.71M | 4.40M | 3.37M | 1.86M | -1.13M | -315.54K | -958.28K | 3.62M | 4.92M | 1.59M | 175.81K | -538.35K | 577.57K | 463.72K | -69.35K | -3.60M | -1.39M | -272.36K | -57.01K | -397.74K | 442.04K | 115.77K | -346.10K | -915.90K | -900.00K | -14.30M | -19.80M | -3.70M |
| Net Income Ratio | -48.89% | 23.34% | 19.57% | 12.27% | -8.79% | -2.72% | -7.41% | 26.47% | 46.14% | 17.93% | 2.69% | -10.42% | 9.98% | 8.32% | -1.59% | -85.13% | -40.30% | -8.23% | -2.12% | -20.32% | 19.93% | 7.66% | -30.11% | -113.23% | -300.00% | -3,575.00% | -860.87% | -616.67% |
| EPS | -0.06 | 0.06 | 0.04 | 0.02 | -0.01 | 0.00 | -0.01 | 0.05 | 0.08 | 0.03 | 0.00 | -0.01 | 0.01 | 0.01 | 0.00 | -0.08 | -0.03 | -0.01 | 0.00 | -0.01 | 0.01 | 0.00 | -0.01 | -0.04 | -0.04 | -0.79 | -1.27 | -0.20 |
| EPS Diluted | -0.06 | 0.06 | 0.04 | 0.02 | -0.01 | 0.00 | -0.01 | 0.05 | 0.08 | 0.03 | 0.00 | -0.01 | 0.01 | 0.01 | 0.00 | -0.08 | -0.03 | -0.01 | 0.00 | -0.01 | 0.01 | 0.00 | -0.01 | -0.04 | -0.04 | -0.79 | -1.27 | -0.20 |
| Weighted Avg Shares Out | 78.27M | 77.96M | 77.67M | 77.59M | 77.19M | 76.20M | 75.34M | 67.68M | 61.80M | 60.90M | 60.28M | 60.28M | 56.56M | 53.22M | 49.58M | 47.05M | 42.34M | 37.19M | 36.34M | 39.77M | 31.57M | 28.94M | 29.36M | 21.23M | 22.50M | 18.10M | 15.59M | 18.50M |
| Weighted Avg Shares Out (Dil) | 78.27M | 78.58M | 78.59M | 78.14M | 77.19M | 76.20M | 75.34M | 71.33M | 65.20M | 62.53M | 60.28M | 60.28M | 56.56M | 53.22M | 49.58M | 47.05M | 42.34M | 37.19M | 36.34M | 39.77M | 34.00M | 28.94M | 29.36M | 21.23M | 22.50M | 18.10M | 15.59M | 18.50M |
Ceapro Inc. Announces the Mailing of Meeting Materials in Connection With the Special Meeting of Securityholders to Approve Merger With Aeterna Zentaris
EDMONTON, Alberta, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSXV: CZO) (OTCQX: CRPOF) (“Ceapro” or the “Company”) is pleased to announce that it has mailed and filed a management information circular dated February 9, 2024 and related meeting materials...
Ceapro Inc. Announces Dosing of First Patients in Phase 1-2a Study Assessing Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases
– Study being led by Dr. Jean-Claude Tardif at the Montreal Heart Institute – No adverse reactions observed, and study can continue as planned EDMONTON, Alberta, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”...
Ceapro Inc. Reports 2023 Third Quarter and Nine-Month Financial Results and Operational Highlights
– Product development focused on the production of powder formulations of oat beta glucan and avenanthramides for cosmeceuticals market
Ceapro Inc. Initiates Phase 1-2a Study Assessing Its Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases
Study being led by Dr. Jean-Claude Tardif at the Montreal Heart Institute Screening of healthy subjects is now underway Phase 1-2a study to provide valuable insights into the safety and activity of avenanthramides in managing conditions related to inflammation EDMONTON,...
Ceapro Inc. Enters into Technical Collaboration with NATEX Prozesstechnologie GmbH and Provides Update on the Scale-Up Project for its Patented Pressurized Gas eXpanded (PGX) Technology
EDMONTON, Alberta, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients and disruptive technologies for healthcare and cosmetic industries, announced...
Ceapro Inc. Reports 2023 Second Quarter and Six-Month Financial Results and Provides Corporate Update
- $5.5 million first six-month 2023 sales vs. $11.7 million for the same period in 2022; sales lagging by one quarter due to stocking campaign by one major customer in 2022 and further Marketplace reorganization
Ceapro Extends Exclusive International Supply and Distribution Agreement with Leading Global Provider of Active Ingredients, Symrise
– Exclusive agreement extended from 3 to 5 years until December 31, 2026 – Supply and distribution agreement provides Symrise with exclusivity for several major key international customers in the cosmetic market – Offering of new preservative free dry product...
Ceapro Announces Next Phase of Research Collaboration with the Angiogenesis Foundation
– New studies to focus on speed of healing and molecular profiling of tissue regeneration induced by oat-derived bioactive products –
Ceapro to Present at the Virtual Investor 2023 Companies to Watch Event
Live video webcast on Wednesday, January 18th at 3:00 PM ET Live video webcast on Wednesday, January 18th at 3:00 PM ET
Ceapro: A Moat In Oat
Ceapro has been steadily building its core business. The company has developed a new technology that offers expansion into adjacent markets and product expansion.
Source: https://incomestatements.info
Category: Stock Reports